Long-term study of mim8 for hemophilia a
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests the long-term safety and effectiveness of the experimental drug mim8 for people with hemophilia A. Depending on the arm, participants may have previously been in a mim8 study, or be infants who have never been treated or had very little treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A, confirmed by medical records
- If you are an adult or child joining from a previous mim8 study (NN7769-4513, 4514, 4516, or 4728), you must have completed certain visits or participated for at least 12 weeks
- If you are under 1 year old with severe hemophilia A, you must have had up to 5 days of treatment for hemophilia in the past
- You can follow the study schedule, keep a diary, and attend visits
- You are not pregnant, breastfeeding, or planning to become pregnant (if female of childbearing potential, you must use highly effective birth control)
- You have not been in another interventional study recently, and you do not have other bleeding or clotting disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This study looks at how often people with hemophilia A develop inhibitors (antibodies that block the effectiveness of factor VIII) after using Coageight, a factor VIII replacement therapy. It may help understand the safety of this treatment.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.